Health Care Select Sector SPDR® Fund
XLV holdings: the top 10 right now
XLV's top 10 holdings make up 60.6% of the fund, and the largest, Eli Lilly and Company, is 17.2% on its own as of 20 November 2026. Seven of the ten are drug makers, so the fund leans far more on medicines than on insurers, hospitals or medical devices.
Holdings and prices as of 20 November 2026. Updated after each market close.
What XLV holds now
XLV, the Health Care Select Sector SPDR Fund, holds the companies in the S&P 500 that are classed as health care: drug makers, biotech firms, health insurers, medical device makers and the companies that supply labs and hospitals. It weights them by market value, and at each quarterly rebalance its index caps single companies and the combined weight of its largest names. As of 20 November 2026, these are its ten largest positions.
| # | Holding | Sector | Weight |
|---|---|---|---|
| 1 | Eli Lilly and CompanyLLY | Healthcare | 17.19% |
| 2 | Johnson & JohnsonJNJ | Healthcare | 9.70% |
| 3 | AbbVie IncABBV | Healthcare | 7.44% |
| 4 | UnitedHealth Group IncorporatedUNH | Healthcare | 5.30% |
| 5 | Merck & Company IncMRK | Healthcare | 5.09% |
| 6 | Thermo Fisher Scientific IncTMO | Healthcare | 3.93% |
| 7 | Amgen IncAMGN | Healthcare | 3.74% |
| 8 | Gilead Sciences IncGILD | Healthcare | 3.12% |
| 9 | Abbott LaboratoriesABT | Healthcare | 2.68% |
| 10 | Intuitive Surgical IncISRG | Healthcare | 2.37% |
The top 10 make up 60.6% of XLV’s 60 holdings. Weights as of 20 November 2026.
A drug-maker fund at the top
The table is dominated by medicines. Drug makers such as Eli Lilly, Johnson & Johnson, AbbVie, Merck, Amgen and Gilead fill most of the ten. UnitedHealth is the only insurer, and the rest are lab-supply and device companies such as Thermo Fisher and Abbott. Hospitals and smaller device makers sit further down the list with much smaller weights.
Eli Lilly and Company stands out. At 17.2% it weighs well over half as much again as the second-largest holding, Johnson & Johnson, so a large share of the fund's day-to-day movement comes from one company and its weight-loss and diabetes drugs.
That matters if you hold XLV to spread risk across health care. Much of the fund rides on a few big drug makers, their patents and their drug prices. A fall in one large drug maker's shares moves XLV more than a bad year for insurers or device makers.
The top 10 against the whole fund
The backtest holds XLV's current top 10 at their fund weights, rescaled to the whole portfolio and rebalanced every quarter, and compares that with holding XLV itself over one, five and ten years.
| 1 year | 5 years | 10 years | |
|---|---|---|---|
| Ending value of $10,000 | |||
| Top 10 basketTop 10 | $12,875 | $27,001 | $73,478 |
| XLV | $11,901 | $14,524 | $29,954 |
| Yearly return | |||
| Top 10 basketTop 10 | 28.8% | 22.0% | 22.1% |
| XLV | 19.0% | 7.8% | 11.6% |
| Worst drop | |||
| Top 10 basketTop 10 | 10.1% | 18.4% | 22.8% |
| XLV | 10.5% | 17.1% | 28.4% |
Windows end 20 November 2026. The top 10 are held at their fund weights rescaled to 100% and rebalanced quarterly; dividends are included on both sides. Hypothetical results: past performance does not predict future returns.
Over five years the top 10 basket returned 22.0% a year against 7.8% for XLV, a gap of +14.2 points a year. Over ten years the gap was +10.5 points. In the last year XLV itself returned 19.0%.
Read that gap with care. Eli Lilly is at the top because its shares rose so far, so a basket built from today's top 10 rewards a run that has already happened. The fund also tells a different story by period: its ten-year return of 11.6% a year is well ahead of its five-year 7.8%, because health care lagged the wider market for several years after the pandemic before the recent rebound.
On risk the picture is mixed. XLV's worst fall was 17.1% over five years and 28.4% over ten. The ten-name basket fell further than the fund over five years but less over ten, so concentration did not always mean a rougher ride.
Before you copy the top 10
- Ten names is a narrower bet. The rest of XLV adds insurers, hospital groups, device makers and smaller biotech firms. A top 10 basket is mostly large drug makers. For a fund built only from biotech companies at roughly equal weights, see the XBI holdings.
- One company drives it. Rescaled to a full portfolio, Eli Lilly's share of a top 10 basket is far bigger than its share of the fund. Many people cap it or switch to equal weights before testing.
- The list changes. UnitedHealth, now outside the top three, was once XLV's largest holding. A copied basket is a snapshot; the fund keeps following its rules.
- Costs and taxes. XLV charges an annual fund fee. A basket of shares has no fund fee but has trading costs and, outside a tax-sheltered account, taxes each time you rebalance.
To test your own version, clone the top 10 into the builder, cap Eli Lilly or switch to equal weights, and backtest it against XLV. For the other sector funds in the same family, see the XLK holdings, XLF holdings and XLE holdings. Health care is also a large part of the VTV value fund, and you can read how rebalancing changes a backtest.
Questions about XLV
What are XLV's top 10 holdings?
As of 20 November 2026, the ten largest positions are in the table above, led by Eli Lilly and Company at 17.2%. Together they make up 60.6% of the fund.
What is the largest holding in XLV?
Eli Lilly and Company, at 17.2% of the fund as of 20 November 2026. It is followed by Johnson & Johnson and AbbVie.
Does XLV hold health insurers?
Yes. UnitedHealth is in the top 10, and other insurers and health care service companies are further down the list, but drug makers carry most of the top 10's weight.
How has XLV performed?
XLV returned 7.8% a year over five years and 11.6% a year over ten, with 19.0% in the last year. Past returns do not tell you what comes next.
Can I backtest my own version of XLV's top 10?
Yes. Clone the top 10 from this page into the Indices Lab builder, change the companies or weights, choose a rebalancing rule, and backtest it against XLV. A free account is enough to start.
About this page. Holdings, weights and prices come from Indices Lab’s own data, powered by EODHD, and every number is recalculated after each market close; the text is reviewed by a person before it is published. Indices Lab is a research and educational tool: everything here is hypothetical and informational, not investment advice and not a recommendation to buy or sell any security. Past performance does not predict future results. See our methodology.